Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 536 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo gel Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

NCT04331080
View directory record Official record
Conditions
Mammoplasty, Scarring, Scar, Breast Reconstruction
Interventions
Granexin® gel 100 μM, Granexin® gel 200 μM, Vehicle gel
Drug
Lead sponsor
Xequel Bio, Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
11
States / cities
Los Angeles, California • Pasadena, California • Doral, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Efficacy and Safety of Voltaren Gel in Subjects With DOMS

NCT02087748
View directory record Official record
Conditions
Pain, Delayed Onset Muscle Soreness
Interventions
1% diclofenac sodium gel, Placebo
Drug
Lead sponsor
Lotus Clinical Research, LLC
Other
Eligibility
18 Years to 35 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue

NCT00490555
View directory record Official record
Conditions
Healthy
Interventions
Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 14, 2026, 7:07 AM EDT
Terminated Phase 3 Interventional Results available

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

NCT03199963
View directory record Official record
Conditions
Mammographic Breast Density
Interventions
4-OH tamoxifen, Placebo
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Mesa, Arizona • Tucson, Arizona • Beverly Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Results available

Eyelid Androgen Treatment in Dry Eye

NCT06154200
View directory record Official record
Conditions
Aqueous Tear Deficiency, Meibomian Gland Dysfunction of Bilateral Eyes (Disorder)
Interventions
Testosterone gel 4.5%, Vehicle gel
Drug
Lead sponsor
Southern California College of Optometry at Marshall B. Ketchum University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 14, 2026, 7:07 AM EDT
Not listed Phase 3 Interventional

Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis

NCT03472144
View directory record Official record
Conditions
Chronic Sinusitis, Ethmoidal, Chronic Sinusitis - Ethmoidal Anterior, Chronic Sinusitis, Chronic Sinusitis - Ethmoidal, Posterior, Chronic Sinusitis, Sphenoidal, Chronic Sinusitis - Frontoethmoidal, Nasal Polyps, Nasal Polyp - Posterior
Interventions
gel loaded with steroids (momentasone), gel loaded with antibiotic (Levofloxacin), gel loaded with both steroids and antibiotic
Drug
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 3 Interventional Results available

Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence

NCT00909181
View directory record Official record
Conditions
Urge Urinary Incontinence, Urinary Frequency
Interventions
Oxybutynin, Placebo
Drug
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
55
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Laguna Hills, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 4 Interventional Results available

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

NCT01753401
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Acthar, Placebo, Steroid Drug
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interventional Study of Mucosal and Antimicrobial Responses to Repeated Vaginal Applications of Tenofovir Gel in HIV Uninfected Women

NCT00594373
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir gel, Tenofovir gel placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 14, 2026, 7:07 AM EDT
Not listed Phase 2 Interventional

Phase 2 Study of TAT4 Gel for Reduction of Nasolabial Folds

NCT02607670
View directory record Official record
Conditions
Nasolabial Folds
Interventions
TAT4 Gel, Matching placebo
Drug
Lead sponsor
Topokine Therapeutics, Inc.
Industry
Eligibility
35 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Results available

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

NCT03927716
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
6 Months and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Mobile, Alabama • Glendale, Arizona • Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Oct 14, 2026, 7:07 AM EDT
Withdrawn Phase 2 Interventional

RCT of SPG Blocks for Post-dural Headache

NCT03560349
View directory record Official record
Conditions
Post-Dural Puncture Headache
Interventions
Lidocaine HCl Gel 2%, placebo gel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Results available

Multisite Controlled Trial of Cocaine Vaccine

NCT00969878
View directory record Official record
Conditions
Cocaine Dependence
Interventions
TA-CD Vaccination, Placebo Injection
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 14, 2026, 7:07 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

NCT00467987
View directory record Official record
Conditions
Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
Interventions
androgel, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
31 Years to 60 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 2 Interventional

Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee

NCT01768975
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
OLT1177 Gel, Placebo gel
Drug · Other
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
DeLand, Florida • South Miami, Florida • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

NCT00656474
View directory record Official record
Conditions
Wounds
Interventions
Placebo gel, GLYC-101 gel (1.0 %)
Drug
Lead sponsor
TR Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study of Lidocaine Vaginal Gel for Recurrent Dysmenorrhea (Painful Periods)

NCT00651313
View directory record Official record
Conditions
Dysmenorrhea
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Winston-Salem, North Carolina • Memphis, Tennessee • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of 4-Hydroxytamoxifen Gel on Breast Density, Salivary Sex Steroids, and Quality of Life in Premenopausal Women

NCT00084344
View directory record Official record
Conditions
Breast Cancer
Interventions
4-hydroxytamoxifen, breast imaging study, radiomammography
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Adapalene Gel 0.1% and to Differin Gel in the Treatment of Acne Vulgaris

NCT04797793
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene Gel 0.1%, Placebo Control, Differin® Gel (Adapalene 0.1%, Galderma)
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
978 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Not applicable Interventional

The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism

NCT02200263
View directory record Official record
Conditions
Ocular Albinism (OA), Oculocutaneous Albinism (OCA)
Interventions
Lutein plus Zeaxanthin, Placebo
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of DSC127 in Treating Subjects With Diabetic Ulcers

NCT00796744
View directory record Official record
Conditions
Foot Ulcer, Diabetic, Diabetic Foot
Interventions
NorLeu3-A(1-7) in a gel formulation
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Tucson, Arizona • Castro Valley, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 14, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00907387
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
RT001, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
9
States / cities
Birmingham, Alabama • San Francisco, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 14, 2026, 7:07 AM EDT
Withdrawn Phase 2 Interventional

Testosterone for Fatigue in Men With MS

NCT03000127
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
AndroGel 1 % Topical Gel, Placebos
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Los Angeles, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 14, 2026, 7:07 AM EDT